These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3938711)

  • 1. Laboratory and clinical studies on amikacin.
    Wang QN; Du JZ; Liu YH; Jiang YF; Sheng JQ; Qiu ZD; Luo MY
    Chin Med J (Engl); 1985 Nov; 98(11):807-16. PubMed ID: 3938711
    [No Abstract]   [Full Text] [Related]  

  • 2. [Control of the resistance of gram-negative bacilli to aminoglucosides. Results of a 3-year prospective study with the exclusive use of amikacin].
    Ruiz-Palacios G; Ponce de León S; Sifuentes J; Ponce de León S; Calva J; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Rev Invest Clin; 1986; 38(1):1-6. PubMed ID: 3738260
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amikacin.
    Gleckman R
    Am Fam Physician; 1976 Dec; 14(6):75. PubMed ID: 998471
    [No Abstract]   [Full Text] [Related]  

  • 5. Controlled comparison of amikacin and gentamicin.
    Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
    N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results.
    Faragó E; Kiss J; Gömöry A; Aranyosi J; Juhász I; Mihóczy L
    Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):421-8. PubMed ID: 511416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phenotypes of resistance to aminosides and sensitivity of amikacin in hospitals].
    Witchitz JL; Golstein FW; Pangon B; Christol D; Acar JF
    Nouv Presse Med; 1979 Oct; 8(42):3417-20. PubMed ID: 537886
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical pharmacology of the most frequently used aminoglucosides: gentamycin, tobramycin and amikacin].
    Cuena Boy R; Azanza Perea JR; Echeverría Echepare LM; Honorato Pérez J
    Rev Med Univ Navarra; 1983 Dec; 27(4):21-7. PubMed ID: 6676898
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro susceptibility of gram negative bacteria to amikacin and its comparison with three other aminoglycoside antibiotics.
    Daniel J; Thomas M; Shanmugam J
    Indian J Pathol Microbiol; 1985 Apr; 28(2):115-9. PubMed ID: 3835114
    [No Abstract]   [Full Text] [Related]  

  • 10. Amikacin in the treatment of pyelonephritis.
    Höffler D
    Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):386-91. PubMed ID: 387619
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experimental study of the antibacterial activity and chemotherapeutic effectiveness of amikacin sulfate].
    Lobuseva AN; Kuznetsova SM; Samoĭlova LN
    Antibiot Med Biotekhnol; 1985 Oct; 30(10):776-80. PubMed ID: 4091515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group.
    Klastersky J; Gaya H; Zinner SH; Bernard C; Ryff JC
    J Antimicrob Chemother; 1980 Sep; 6 Suppl A():55-61. PubMed ID: 6252180
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical and bacteriological evaluation of Amikin (Amikacin sulfate) by Bristol-Myers].
    Wencel J; Czaplicki M; Borkowski A; Malewski AW
    Pol Tyg Lek; 1978 Dec; 33(50):1937-8. PubMed ID: 733620
    [No Abstract]   [Full Text] [Related]  

  • 14. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Amikacin therapy for serious infections in hematopoietic disorders (author's transl)].
    Fujii H; Shimizu T
    Jpn J Antibiot; 1981 Jun; 34(6):841-51. PubMed ID: 7289039
    [No Abstract]   [Full Text] [Related]  

  • 16. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
    Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A
    Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aspects of antibacterial therapy using amikacin].
    Grassi GG; Bucci R; Ferrara A
    G Ital Chemioter; 1976; 23(1):47-54. PubMed ID: 1029696
    [No Abstract]   [Full Text] [Related]  

  • 18. [Amikacin in the treatment of Gram negative bacilli septicemias].
    Cartier F; Dien G; Cormier M; Hoel JC; Guivarch G
    Nouv Presse Med; 1979 Oct; 8(42):3510-12. PubMed ID: 537908
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of amikacin sulfate (Amikin). A new aminoglycoside antibiotic.
    Schiffman DO
    JAMA; 1977 Oct; 238(14):1547-50. PubMed ID: 578232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF; Maslow MJ; Leibowitz RE; Pollock AA; Hanna BA; Schaefler S; Simberkoff MS; Rahal JJ
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.